Physician profile
Gary D Levinson
NPI 1255399523
$3,869.44
in general payments reported to CMS, 2019-2025
23 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $149 · 2021: $308 · 2022: $221 · 2023: $574 · 2024: $1,134 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,951.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $986.59 | 2019-2025 | Wegovy, Saxenda, Rybelsus |
| Harmony Biosciences LLC | $737.91 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $302.71 | 2023-2025 | Inspire |
| Lilly USA, LLC | $293.61 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $251.85 | 2024 | Andexxa |
| Glaxosmithkline, LLC. | $181.15 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $174.78 | 2024-2025 | Evenity, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $162.14 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $121.75 | 2019 | |
| Verity Pharmaceuticals INC. | $112.82 | 2024-2025 | Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.57 | 2024-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $63.24 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $59.06 | 2025 | Rexulti |
| Abbvie INC. | $57.94 | 2024-2025 | |
| Pfizer INC. | $56.81 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $43.88 | 2024-2025 | Lumryz |
| Cleerly, INC. | $36.24 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Takeda Pharmaceuticals U.S.A., INC. | $34.23 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.05 | 2024 | |
| 3b Medical, INC. | $26.04 | 2025 | Luna |
| Tolmar, INC. | $25.14 | 2025 | Jatenzo |
| Exact Sciences Corporation | $16.19 | 2025 | |
| Intra-Sana Laboratories | $14.74 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.